HUTCHMED Initiates Phase II/III Trial of the Combination of

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Shanghai , China , Hong Kong , Ben Atwell Alex Shaw , Hengrui Pharma , Zhou Yi , Weiguo Su , Atholl Tweedie , China National Reimbursement Drug List , Drug Administration , Stock Exchange Of Hong Kong , Exchange Commission , Linkedin , China Limited , Jiangsu Hengrui Pharmaceuticals Co Ltd Pharma , Nasdaq , Chief Executive Officer , Chief Scientific Officer , Cancers Symposium , Orphan Drug Designation , New Drug Application , Drug User Fee Act , Pharma Exec , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , Alex Shaw , Global Cancer Observatory , World Fact , Accessed April ,